@article {7676,
	title = {A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: Time-dependent effect of 4 versus 6 cycles on outcome},
	journal = {Oncology},
	volume = {81},
	year = {2011},
	note = {Cited By :1Export Date: 21 February 2017},
	month = {2011},
	pages = {365 - 371},
	abstract = {Objective: We investigated the efficacy of risk-adapted adjuvant paclitaxel/carboplatin chemotherapy in early-stage ovarian carcinoma. Methods: Fifty-three patients were treated according to the risk of relapse: patients with stages IA or IB or with grade 1 (low risk) received 4 cycles of paclitaxel and carboplatin; patients with IC/IIA and grade 2 or 3 (high risk) received 6 cycles of chemotherapy. The outcome was compared with that of 95 patients who were all treated with 4 cycles. Results: Median follow-up was 88, 113 and 42 months for the whole cohort, non-risk-adapted and risk-adapted treatment, respectively. Five-year relapse-free and diseasespecific survival was 86 and 93\% for the whole population, 96 and 97\% for low-risk and 81 and 91\% for high-risk patients. Risk classification was the only significant prognostic factor for relapse-free (p = 0.011) and disease-specific survival (p = 0.039). Among high-risk patients, the administration of 6 cycles was associated with a significantly lower relapse rate after censoring events, which occurred beyond 2 years (3 vs. 18\%; p = 0.013), but this difference was diminished at 5 years (23 vs. 25\%; p = 0.797). Conclusions: Six cycles of chemotherapy reduced the risk of relapse within 2 years, but the benefit from two additional cycles beyond this time is questionable. Copyright {\textcopyright} 2012 S. Karger AG, Basel.},
	keywords = {Chemotherapy, Early stage, Ovarian cancer, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855812024\&doi=10.1159\%2f000334230\&partnerID=40\&md5=795b2e75711bc8cd74ef22ee6d40e74c},
	author = {Bamias, A. and Bamia, C. and Karadimou, A. and Soupos, N. and Zagouri, F. and Rodolakis, A. and Haidopoulos, D. and Vlahos, G. and Thomakos, N. and Antsaklis, A. and Dimopoulos, M.A.}
}
